CD141+CLEC9A+ Dendritic Cell Production Without Feeder Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating conventional type 1 dendritic cells (cDC1s) are limited by their low prevalence in the blood and reliance on feeder cells, which complicates their clinical application in immunotherapy, particularly for cancer treatment.
Innovation Solution
A method for producing high numbers of CD141+CLEC9A+ cDC1-like cells in vitro from mobilized CD34+ hematopoietic stem cells using FLT3L and GM-CSF without feeder cells, cultured on non-tissue culture-treated surfaces, enhancing their antigen-presenting capabilities and immune response activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods are used to generate cDC1s from blood, then the process is simple, but the yield is low due to low prevalence of cDC1s in blood
Solution Approach 1:
The patent performs preliminary expansion of cDC1 precursors in vitro before differentiation, using FLT3L and GM-CSF cytokines to expand the precursor pool ex vivo. This preliminary action overcomes the low in vivo prevalence of cDC1s by generating sufficient numbers of precursors before they are differentiated into functional cDC1s, thereby resolving the contradiction between low blood prevalence and high productivity requirement.
2Reliability
If feeder cells are used in cDC1 generation, then cell differentiation is supported, but the process complexity increases
Solution Approach 1:
The patent extracts and eliminates the feeder cell component from the differentiation system, replacing it with a defined cytokine environment (FLT3L and GM-CSF). This removal of unnecessary complexity while maintaining differentiation efficiency through cytokine signaling resolves the contradiction between reliable differentiation and process simplicity.
Solution Approach 2:
The patent introduces cytokines (FLT3L and GM-CSF) as intermediary molecules that mediate the differentiation process without requiring direct cell-to-cell contact or feeder cells. These cytokines serve as soluble mediators that transmit differentiation signals, replacing the complex feeder cell system with a simpler biochemical signaling approach while maintaining reliability.
3Productivity
If monocyte-derived DCs are used, then large numbers can be produced, but antigen cross-presentation capability is inferior
Solution Approach 1:
The patent applies local quality by creating a specialized differentiation environment using specific cytokine combinations (FLT3L and GM-CSF) that induce cDC1-specific properties. This localized optimization of differentiation conditions ensures that the produced DCs possess the specific cross-presentation capability characteristic of cDC1s, rather than the inferior capability of monocyte-derived DCs, while still achieving high productivity.
Data Source
AI summary
The present disclosure describes systems and methods for in vitro differentiation of human cross-presenting CD141+CLEC9A+ dendritic cells from mobilized peripheral blood CD34+ hematopoietic stem cells. The dendritic cells may further comprise an antigen or nucleic acid encoding an antigen. Methods of using the cells are also provided.